{
    "clinical_study": {
        "@rank": "149650", 
        "arm_group": [
            {
                "arm_group_label": "CNV secondary to CSC"
            }, 
            {
                "arm_group_label": "CSC without CNV"
            }, 
            {
                "arm_group_label": "CNV secondary to advanced AMD"
            }
        ], 
        "biospec_descr": {
            "textblock": "Buccal cells"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The study will be designed as a case control evaluation to compare the genetic profiles of\n      three  groups of patients categorized according to diagnosis.\n\n      Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced\n      AMD."
        }, 
        "brief_title": "Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Age Related Macular Degeneration", 
            "Choroidal Neovascularization", 
            "Central Serous Chorioretinopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Neovascularization, Pathologic", 
                "Choroidal Neovascularization", 
                "Central Serous Chorioretinopathy"
            ]
        }, 
        "detailed_description": {
            "textblock": "To determine if patients presenting with type 1 neovascularization believed to be secondary\n      to CSC are genetically distinct from typical CSC patients without neovascularization or\n      patients presenting with choroidal neovascularization (CNV) secondary to advanced AMD.\n      Disease associated markers detecting variants in ARMS 2, Complement Factor H (CFH)\n      Complement component 3 (C3), Complement component 2 (C2) , Factor B (FB), VEGFA or other\n      genetic polymorphisms associated with CNV will be evaluated to determine if the CSC\n      neovascular group is genetically distinct from the CSC group without neovascularization or\n      the advanced AMD group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Caucasian\n\n          -  30 years and older (CSC)\n\n          -  50 years and older (Advanced AMD)\n\n          -  Genders Eligible for Study:   Both\n\n          -  Completed Consent form\n\n          -  Diagnosis of choroidal neovascularization in at least one eye\n\n        Exclusion Criteria:\n\n          -  Patient age less than 30 years (CSC).\n\n          -  Patient age less than 50 years (AMD).\n\n          -  Presence of retinal disease involving the photoreceptors and/or outer retinal layers\n             other than AMD and CSC such as high myopia, retinal dystrophies, retinal vein\n             occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which\n             have been present prior to the age of 30.\n\n          -  Opacities of the ocular media, limitations of pupillary dilation or other problems\n             sufficient to preclude adequate fundus photography.\n\n          -  Missing informed consent\n\n          -  Previous sample donation under this protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients seen for routine visits at the offices of Vitreous Retina Macula Consultants of\n        New York.\n\n        Enrollment will include 150 subjects: 50 will be selected based on diagnosis of CNV\n        secondary to CSC 50 will be selected based on diagnosis of CSC without neovascularization\n        and 50 selected based on diagnosis of CNV secondary to advanced AMD."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880788", 
            "org_study_id": "SCMM-AMD-107"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Age Related Macular Degeneration", 
            "Choroidal Neovascularization", 
            "Central Serous Chorioretinopathy"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "contact": {
                "email": "mlee@vrmny.com", 
                "last_name": "May Lee", 
                "phone": "212-452-6965"
            }, 
            "facility": {
                "address": {
                    "city": "New York City", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10022"
                }, 
                "name": "Vitreous Retina Macula Consultants of New York"
            }, 
            "investigator": {
                "last_name": "Bailey Freund, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Evaluation of Genetic Variants in Patients With Type 1 Neovascularization (Sub-retinal Pigment Epithelium Neovascularization) Who Lack Typical Findings of Age Related Macular Degeneration (AMD) But Present With Findings More Consistent With Long-standing Central Serous Chorioretinopathy (CSC).", 
        "overall_contact": {
            "email": "kbfnyf@aol.com", 
            "last_name": "Bailey Freund, MD", 
            "phone": "(212) 861-9797"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The identification of individual genetic markers or a quantitative measure of total genetic burden associated with CNV secondary to CSC vs. CSC vs. CNV secondary to advanced AMD as meaured by the commercially available RetnaGene AMD assay.", 
            "measure": "Total genetic burden", 
            "safety_issue": "No", 
            "time_frame": "Baseline assessment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880788"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vitreous -Retina- Macula Consultants of New York", 
            "investigator_full_name": "K. Bailey Freund, MD", 
            "investigator_title": "Clinical Associate Professor at NYU School of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Sequenom, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Vitreous -Retina- Macula Consultants of New York", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sequenom, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}